<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097781</url>
  </required_header>
  <id_info>
    <org_study_id>RuijinHDR</org_study_id>
    <nct_id>NCT05097781</nct_id>
  </id_info>
  <brief_title>Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients</brief_title>
  <official_title>Evaluating the Efficacy of Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors: a Phase II Prospective Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study to observe efficacy of combining local radiotherapy with&#xD;
      PD-1blockade in patients with advanced solid tumors. All patients will accept at least one&#xD;
      site of radiotherapy together with PD-1 blockade. The study will evaluate changes of&#xD;
      unirradiated and irradiated lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed at least 4 weeks</time_frame>
    <description>The proportion of patients with a tumor volume reduction of 30% lasting for at least 4 weeks，and is the sum of the proportion of complete remission (CR) and partial remission (PR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>non-irradiated lesion control rate(NRCR)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>The percentage of non-irradiated target lesions with CR/PR or SD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>The time from enrollment to disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>The time from enrollment to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of side effects</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>≥ grade 3 adverse effects</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local irradiation + immunotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 blocking antibody</intervention_name>
    <description>All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients 18-75 years old with the right to make medical decisions&#xD;
&#xD;
          2. Signed informed consent form&#xD;
&#xD;
          3. ECOG score of 0-2&#xD;
&#xD;
          4. Clear pathological diagnosis of the primary site&#xD;
&#xD;
          5. Multiple distant metastases&#xD;
&#xD;
          6. Stable assessment of brain metastases after treatment can be enrolled (more than 6&#xD;
             weeks)&#xD;
&#xD;
          7. Bone metastases combined with soft tissue mass formation can be enrolled&#xD;
&#xD;
          8. imaging with ≥ 2 clearly assessable lesions (bone metastases alone without soft tissue&#xD;
             mass formation, brain metastases not as target lesions)&#xD;
&#xD;
          9. expected survival ≥ 6 months&#xD;
&#xD;
         10. Progression after ≥ 1 prior line of therapy regimen with no standard treatment regimen&#xD;
             or intolerable toxicities, including all three of the following:&#xD;
&#xD;
               1. Patients must have failed to respond to at least one prior standard of care&#xD;
                  regimen&#xD;
&#xD;
               2. The patient must not have a conventional treatment option that is clinically&#xD;
                  proven to provide long-term control of the disease and the patient refuses other&#xD;
                  conventional treatment options&#xD;
&#xD;
               3. The patient is intolerant to the toxic side effects of the standard treatment&#xD;
                  regimen&#xD;
&#xD;
         11. No prior immunotherapy history&#xD;
&#xD;
         12. Time to last systemic therapy (including monoclonal antibodies) ≥ 4 weeks&#xD;
&#xD;
         13. Previous radiotherapy to non-target sites with other evaluable lesions can be enrolled&#xD;
&#xD;
         14. Laboratory examination indexes meet the following requirements: WBC ≥ 3×109/L, ANC ≥&#xD;
             2.0×109/L, PLT ≥ 80×109/L, Hb ≥ 80g/L (according to the normal standards of the&#xD;
             central laboratory department); liver function: total bilirubin, ALT and AST are ≤&#xD;
             1.5xUNL (upper limit of normal value); AST (SGOT)/ALT (SGPT) ≤ 2.5xUNL (upper limit of&#xD;
             normal value) ALT (SGPT) ≤ 2.5 x IULN (upper limit of normal value); renal function:&#xD;
             Cr≦1.5xUNL (upper limit of normal value), and creatinine clearance rate≧60ml/min;&#xD;
             thyroid function T3, T4 within normal range (hypothyroidism can be supplemented with&#xD;
             oral thyroxine); cardiac function: cardiac protein three and pro-BNP within normal&#xD;
             range, no previous Adrenal function: normal cortisol secretion function or correctable&#xD;
             by endocrine assessment&#xD;
&#xD;
         15. HBV infected patients with HBV-DNA copy number less than 500 IU/ml&#xD;
&#xD;
         16. No history of other malignancies within 5 years (except skin basal cell carcinoma)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled brain metastases (stabilization time &lt;6 weeks)&#xD;
&#xD;
          2. Bone metastases alone without clear soft tissue mass formation&#xD;
&#xD;
          3. Bone marrow infiltration&#xD;
&#xD;
          4. Presence of clinical factors (e.g., bleeding, active infection, or psychiatric&#xD;
             factors) that the investigator determines may interfere with the completion of the&#xD;
             study process&#xD;
&#xD;
          5. Inability to administer radiotherapy due to organ-threatening or other factors as&#xD;
             assessed by the investigator&#xD;
&#xD;
          6. Patients requiring long-term maintenance steroid therapy (including oral, intravenous&#xD;
             use); topical use or inhalation may be included in the study&#xD;
&#xD;
          7. Prior autoimmune disease or active disease [e.g., including but not limited to&#xD;
             inflammatory bowel disease [IBD], rheumatoid arthritis, autoimmune hepatitis, systemic&#xD;
             sclerosis (scleroderma and its variants), systemic lupus erythematosus, autoimmune&#xD;
             vasculitis, autoimmune neuropathy (e.g., Guillain-Barre syndrome)], vitiligo and&#xD;
             correctable endocrine deficiencies such as thyroid hypofunction, physiological&#xD;
             cortisol hypersecretion may be included in the study and are not considered as&#xD;
             exclusion criteria.&#xD;
&#xD;
          8. history of active tuberculosis or non-infectious pneumonia or any clinical evidence&#xD;
&#xD;
          9. Active viral hepatitis with HBV DNA &gt; 500 IU/ml&#xD;
&#xD;
         10. Immunodeficiency syndrome&#xD;
&#xD;
         11. comorbid serious medical disorders with concomitant diseases or conditions affecting&#xD;
             the normal enrollment of the patient or safety during the study&#xD;
&#xD;
         12. previous immunotherapy for other tumors&#xD;
&#xD;
         13. History of other malignancies within 5 years (except cured basal cell carcinoma of the&#xD;
             skin);&#xD;
&#xD;
         14. Pregnant or lactating women;&#xD;
&#xD;
         15. Unable or unwilling to sign the informed consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiayi Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yujie Wang, MD</last_name>
    <phone>8602164370045</phone>
    <phone_ext>602400</phone_ext>
    <email>wyj12054@rjh.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yunsheng Gao, MD</last_name>
    <email>gys11856@rjh.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiayi Chen, MD</last_name>
      <phone>+86-021-64370045</phone>
      <phone_ext>602400</phone_ext>
      <email>cjy11756@rjh.com.cn</email>
    </contact>
    <investigator>
      <last_name>Jiayi Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 16, 2021</last_update_submitted>
  <last_update_submitted_qc>October 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Jiayi Chen</investigator_full_name>
    <investigator_title>Chief of Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Blocking</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

